Lodazecar

This classification denotes an anti-lipidemic agent with the molecular formula C22H24BrClN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4D9016A00, chemically known as 1-(1,1-bis(hydroxymethyl)ethyl)-3-((s)-6-bromo-5-(o-chlorophenyl)-2,3-dihydro-1,3-dimethyl-2-oxo-1h-1,4-benzodiazepin-7-yl)urea but generally known as lodazecar, which bears US NIH Compound Identifier 65657. European Medicines Agency schedules Lodazecar in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08548MIG. The term LODAZECAR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). LODAZECAR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lodazecar under HS 29339940 and SITC 51577. As of Q4 2014, LODAZECAR remains the US FDA Preferred Term for this commodity. Lodazecar bears US NLM identifiers UMLS ID C2825677 and NCI Concept Code C81538. SMILES: Brc1c2c(N(C(=O)C(N=C2c2c(Cl)cccc2)C)C)ccc1NC(=O)NC(CO)(CO)C.